Now Reading: L&C Bio develops fat injection to treat ‘Ozempic face’
-
01
L&C Bio develops fat injection to treat ‘Ozempic face’
South Korean biotech L&C Bio has developed an injectable treatment from donated human fat to restore facial volume lost due to weight-loss drugs like Ozempic. CEO Lee Whan Chul says the product,…
The Story in Brief
South Korean biotech L&C Bio has developed an injectable treatment from donated human fat to restore facial volume lost due to weight-loss drugs like Ozempic. CEO Lee Whan Chul says the product, tentatively named MegaAdipoECM, acts as a scaffold for the patient's own fat cells. The company holds patents in South Korea, the US and China.
Commercialisation was blocked because South Korean law classified donated fat as medical waste. Parliament legalised reuse this year, and L&C Bio expects to launch after a one-year grace period, likely in late 2027. Bloomberg reports the company had considered manufacturing in Singapore or the US. Critics argue the technology could divert resources from burn victims, but Lee says donors consent to cosmetic use and supports stronger regulation.
The Indian Opinion
The rush to profit from 'Ozempic face' creates a fresh dilemma. Critics who worry that donated human tissue meant for burn victims could be diverted for cosmetic fixes have a point. But banning aesthetic use outright would ignore that donors consent to it. The real test is regulation. South Korea's new law allows reuse of medical waste fat, but does it safeguard against exploitation? The number of donors and clear consent forms will tell us if this market stays ethical.
Source: businesstoday.in
This story was synthesised by AI from the source linked above.
